• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4106.TW
Share

Wellell Inc. Stocks

NT$ 24.8Last Updated 27.07.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 77.74M

NT$ 24.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1990 in New Taipei City, Taiwan, Wellell Inc. is a global enterprise active in the medical supplies sector. The company's activities span research and development, manufacturing, and the international distribution (import, export, and sales) of its diverse product portfolio. This includes items for wound care, respiratory therapy devices, assistive welfare equipment, and other electronic medical instruments. Wellell's specific offerings feature pressure relief mattresses and seating, as well as advanced solutions for sleep apnea, such as auto-adjusting pressure systems and their Sleepwell product line. These innovative solutions primarily focus on the prevention of pressure injuries and the management of obstructive sleep apnea.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, under

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 23:55

"Just Like a Nike Sneaker Drop": Ford Has Figured Out How to Boost Profits Through Customization

27.07.2026 23:27

Dior's owner reported an increase in sales of clothing and handbags for the first time in two years

27.07.2026 22:53

Nvidia formed an AI safety alliance following an accidental hack carried out by OpenAI

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

27.07.2026 22:13

Plata has appointed the former U.S. ambassador to Russia to its board of directors

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026